CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Inclusion Criteria: * Patients with CD19+ leukemia or lymphoma, meeting the following criteria: * At least 2 prior combination chemotherapy regimens (not including single agent monoclonal antibody (Rituximab) therapy) * Less than 1 year between last chemotherapy and progression * Not eligible or appropriate for allo-HSCT * To be aged 6 to 85 years * Estimated survival of ≥ 6 months, but ≤ 2 years * ECOG score ≤2 * Relapse after auto-HSCT * Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time * Voluntary participation in the clinical trials and sign the informed consent Exclusion Criteria: * History of epilepsy or other CNS disease * Patients have GVHD, which needs treatment with immunosuppressive agents * Patients with prolonged QT interval or severe heart disease * Patients in pregnancy or breast-feeding period * Uncontrolled active infection * Active hepatitis B or hepatitis C infection * Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary * Previously treatment with any gene therapy products * Feasibility assessment during screening demonstrates \<20% transduction of target lymphocytes, or insufficient expansion (\<5-fold) in response to CD3/CD28 costimulation * ALT /AST\>3 x normal value; Creatinine\> 2.5 mg/dl; Bilirubin \>2.0 mg/dl * Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial * HIV infection * Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation